3rd Generation COVID-19 Vaccines May Offer SARS Cross-Protection
According to a very small study published by The New England Journal of Medicine on August 18, 2021, people with a previous SARS-1 infection who received Comirnaty (Pfizer - BioNTech) vaccination had a cross-clade boost of broad-spectrum neutralizing antibodies.
These study participants generated very high levels of neutralizing antibodies against both the original SARS-CoV-1 and new SARS-CoV-2 betacoronavirus after only (1) dose of the mRNA-based Comirnaty vaccine.
This study concluded by saying, 'Further investigation is needed to address whether serial administration of vaccines based on two distantly related S or RBD proteins in the reverse order — that is, priming from the SARS-CoV-2 clade followed by boosting from the SARS-CoV-1 clade — will produce a similar level of pan-sarbecovirus neutralizing antibodies.'
'If successful, this will lay a strong foundation for the development of a third-generation Covid-19 vaccine for controlling current and emerging (SARS) variants of concern, as well as for preventing future sarbecovirus pandemics.'
Note: This study was supported by grants from the Singapore National Research Foundation and National Medical Research Council. No conflicts of interest were disclosed.